Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

fMRI Cholinergic Mechanisms in Schizophrenia

This study has been completed.
Information provided by (Responsible Party):
VA Office of Research and Development Identifier:
First received: August 27, 2010
Last updated: May 12, 2015
Last verified: May 2015
This study aims to determine how clozapine treatment improves neuronal measures of sensory gating in subjects with schizophrenia.


Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Cross-Sectional
Official Title: fMRI Cholinergic Mechanisms in Schizophrenia

Resource links provided by NLM:

Further study details as provided by VA Office of Research and Development:

Primary Outcome Measures:
  • Neuronal Response During Sensory Gating [ Time Frame: Immediate ]
    Neuronal response (blood oxygenation level dependent functional magnetic resonance imaging signal, relative to the global mean) during sensory gating. Sensory gating is defined as the process of filtering out unnecessary environmental stimuli.

Enrollment: 40
Study Start Date: October 2008
Study Completion Date: December 2011
Primary Completion Date: December 2011 (Final data collection date for primary outcome measure)
Patients with schizophrenia treated with clozapine

Detailed Description:
This study will use functional magnetic resonance imaging (fMRI) to study patients treated with risperidone, a commonly used neuroleptic that does not improves sensory gating, to those treated with clozapine to determine which brain areas are involved in clozapine's normalization of sensory gating in schizophrenia.

Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Subjects with schizophrenia

Inclusion Criteria:

  • Diagnosis of schizophrenia
  • age 18-60 yrs

Exclusion Criteria:

  • claustrophobia
  • weight > 250 lbs
  • metal in body other than dental fillings
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01191827

United States, Colorado
VA Eastern Colorado Health Care System, Denver
Denver, Colorado, United States, 80220
Sponsors and Collaborators
VA Office of Research and Development
Principal Investigator: Jason R. Tregellas, PhD VA Eastern Colorado Health Care System, Denver
  More Information

Responsible Party: VA Office of Research and Development Identifier: NCT01191827     History of Changes
Obsolete Identifiers: NCT00692679
Other Study ID Numbers: MHBB-011-07F
Study First Received: August 27, 2010
Results First Received: December 23, 2014
Last Updated: May 12, 2015

Additional relevant MeSH terms:
Schizophrenia Spectrum and Other Psychotic Disorders
Mental Disorders
Cholinergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs processed this record on May 23, 2017